

1 **Title**

2 Epigenomic signature of major congenital heart defects in newborns with Down syndrome

3

4 **Authors**

5 Julia S. Mouat^{1,2,3,4}, Shaobo Li⁵, Swe Swe Myint⁵, Benjamin I. Laufer^{1,2,3,4}, Philip J. Lupo⁶,

6 Jeremy M. Schraw⁶, John P. Woodhouse⁶, Adam J. de Smith^{*5}, Janine M. LaSalle^{*1,2,3,4}

7 *Equal contributors

8 Corresponding author: Janine LaSalle, jmlasalle@ucdavis.edu

9

10 **Affiliations**

11 ¹Department of Medical Microbiology and Immunology, School of Medicine, University of
12 California, Davis, CA USA

13 ²Perinatal Origins of Disparities Center, University of California, Davis, CA USA

14 ³Genome Center, University of California, Davis, CA USA

15 ⁴MIND Institute, University of California, Davis, CA USA

16 ⁵Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck
17 School of Medicine, University of Southern California, CA USA

18 ⁶Division of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine,
19 Houston, TX USA

20

21

22

23

24

25

26

27 **ABSTRACT**

28 **Background:** Congenital heart defects (**CHDs**) affect approximately half of individuals with Down
29 syndrome (**DS**) but the molecular reasons for incomplete penetrance are unknown. Previous
30 studies have largely focused on identifying genetic risk factors associated with CHDs in
31 individuals with DS, but comprehensive studies of the contribution of epigenetic marks are lacking.
32 We aimed to identify and characterize DNA methylation differences from newborn dried blood
33 spots (**NDBS**) of DS individuals with major CHDs compared to DS individuals without CHDs.

34
35 **Methods:** We used the Illumina EPIC array and whole-genome bisulfite sequencing (**WGBS**) to
36 quantitate DNA methylation for 86 NDBS samples from the California Biobank Program: 1) 45
37 DS-CHD (27 female, 18 male) and 2) 41 DS non-CHD (27 female, 14 male). We analyzed global
38 CpG methylation and identified differentially methylated regions (**DMRs**) in DS-CHD vs DS non-
39 CHD comparisons (both sex-combined and sex-stratified) corrected for sex, age of blood
40 collection, and cell type proportions. CHD DMRs were analyzed for enrichment in CpG and genic
41 contexts, chromatin states, and histone modifications by genomic coordinates and for gene
42 ontology enrichment by gene mapping. DMRs were also tested in a replication dataset and
43 compared to methylation levels in DS vs typical development (**TD**) WGBS NDBS samples.

44
45 **Results:** We found global CpG hypomethylation in DS-CHD males compared to DS non-CHD
46 males, which was attributable to elevated levels of nucleated red blood cells and not seen in
47 females. At a regional level, we identified 58, 341, and 3,938 CHD-associated DMRs in the Sex
48 Combined, Females Only, and Males Only groups, respectively, and used machine learning
49 algorithms to select 19 Males Only loci that could distinguish CHD from non-CHD. DMRs in all
50 comparisons were enriched for gene exons, CpG islands, and bivalent chromatin and mapped to
51 genes enriched for terms related to cardiac and immune functions. Lastly, a greater percentage

52 of CHD-associated DMRs than background regions were differentially methylated in DS vs TD
53 samples.

54
55 **Conclusions:** A sex-specific signature of DNA methylation was detected in NDBS of DS-CHD
56 compared to DS non-CHD individuals. This supports the hypothesis that epigenetics can reflect
57 the variability of phenotypes in DS, particularly CHDs.

58
59 **Keywords**
60 Down syndrome, congenital heart defect, newborn dried blood spot, DNA methylation, whole-
61 genome bisulfite sequencing, epigenetics, epigenome-wide association study, differentially
62 methylated regions, nRBC, hypomethylation

63
64 **List of abbreviations:**
65 DS: Down syndrome
66 CHD: Congenital heart defect
67 AVSD: Atrioventricular septal defect
68 WGBS: Whole-genome bisulfite sequencing
69 NDBS: Newborn dried blood spot
70 TD: Typical development
71 DMR: Differentially methylated region
72 QC: Quality control
73 nRBC: Nucleated red blood cell
74 PCA: Principal component analysis
75 EPO: Erythropoietin
76 TAM: Transient abnormal myelopoiesis

77

78 **MANUSCRIPT**

79

80 **1. Introduction**

81 Down syndrome (**DS**) is a set of distinct clinical features that result from trisomy 21, the most
82 common autosomal aneuploidy across live births. Clinical characteristics of DS vary across
83 individuals but include intellectual disability, short stature, muscle hypotonia, atlantoaxial
84 instability, reduced neuronal density, cerebellar hypoplasia, and congenital heart defects (**CHDs**)
85 (1). CHDs affect ~50% of newborns of both sexes with DS (2–5) despite their diagnosis in only
86 ~1% of newborns without DS (6). The most frequently diagnosed CHD in children with DS is an
87 atrioventricular septal defect (**AVSD**), a condition characterized by a large hole in the heart due
88 to improper development of the endocardial cushion. Many cases of DS-CHDs, particularly AVSD,
89 are diagnosed *in utero* by ultrasound, but others are not diagnosed until after birth following
90 obvious symptoms or an echocardiogram and often require surgery.

91

92 The mechanisms influencing the development of CHDs among individuals with DS are not clear.
93 Studies of partial trisomy 21 patients have pinpointed critical regions on chromosome 21,
94 including the Down syndrome cell adhesion molecule (*DSCAM*) gene, that appear to underlie
95 CHD development (7), but these have not addressed the incomplete penetrance among
96 individuals with complete trisomy 21. Additionally, genome-wide association studies and
97 candidate-gene approaches have identified variants on chromosomes throughout the genome
98 that are associated with CHDs in DS (8–13). However, these genetic variants do not sufficiently
99 explain CHD risk among those with DS.

100

101 Another molecular driver or biomarker of CHD risk in children with DS may be epigenetic
102 mechanisms such as DNA methylation. Increasing evidence has shown epigenetic alterations
103 and gene-environment interactions to be involved in the pathogenesis of non-syndromic CHDs

104 (14,15), but comprehensive studies of genome-wide DNA methylation variation associated with
105 DS-CHD are lacking. We previously used whole-genome bisulfite sequencing (**WGBS**) of
106 newborn dried blood spots (**NDBS**) to examine methylation profiles in 11 DS-CHD compared to
107 10 DS non-CHD samples, as part of a larger DS vs typical development (**TD**) study (16). There
108 were 1,588 nominally significant ($p < 0.05$) differentially methylated regions (**DMRs**) (35%
109 hypermethylated, 65% hypomethylated) distinguishing DS-CHD from DS non-CHD and these
110 regions were enriched for terms related to the heart, as well as neurodevelopment and
111 metabolism (16). These promising but preliminary results suggesting an epigenomic signature of
112 CHD within DS led us to conduct the present study.

113
114 This current study used WGBS of NDBS obtained from the California Biobank Program among
115 86 DS individuals with and without major CHDs to identify specific loci, biological pathways, and
116 genic contexts that are associated with risk for CHDs in the DS population. Very few studies have
117 conducted WGBS on NDBS, a sample source that is accessible, widely banked, reflective of the
118 intrauterine period, and informative regarding dysregulation in other tissues, including the brain
119 and the heart (16). In contrast to reduced representation methods such as arrays, this WGBS
120 study provides insight to the entire DS-CHD epigenome, particularly because regional methylation
121 smoothing approaches increase confidence over regions with relatively low coverage.
122 Additionally, our study investigates similarities/differences in molecular signatures of DS-CHD in
123 males compared to females, as well as DS-CHD compared to DS (versus TD). Our findings
124 showed sex-specific global and region-specific changes to methylation that may serve as
125 biomarkers and/or be functionally important in the development of CHDs in individuals with DS.

126

127 **2. Methods**

128 **2.1 Study Populations and DNA extraction from NDBS**

129 This study was approved by Institutional Review Boards at the California Health and
130 Human Services Agency, University of Southern California, and University of California,
131 Davis. For the Discovery study, deidentified NDBS were obtained from 90 newborns with
132 DS from the California Biobank Program (CBP, SIS request number 572), with a waiver
133 of consent from the Committee for the Protection of Human Subjects of the State of
134 California (17). Demographic and birth-related data, including sex, race/ethnicity,
135 birthweight, gestational age, and age of blood collection were obtained from the CBP
136 **(Supplemental Tables S1-S2)**. DS newborns with CHD or without CHD were identified
137 via linkage between the California Department of Public Health Genetic Disease
138 Screening Program and the California Birth Defects Monitoring Program (CBDMP). In
139 brief, the CBDMP is a population-based surveillance program that covers ~30% of the
140 births in California, including 10 counties, which are representative of the state's
141 population (18). Birth defects diagnosis data from CBDMP for the 90 newborns were
142 coded into "major birth defects" and "major heart defects" using guidelines from the
143 National Birth Defects Prevention Network (6). Major defects included AVSD and tetralogy
144 of Fallot. We identified 46/90 newborns with a CHD, of which 44 were AVSDs, and 3 had
145 tetralogy of Fallot. For this study, we focused on major heart defects and following sample
146 QC (described below) we included 45 DS with CHD (27 female, 18 male) and 41 DS
147 without CHD (27 female, 14 male). DNA was extracted from one 4.7 mm card punch of
148 each of the 90 NDBS, roughly 1.4cm in diameter, with the Beckman Coulter GenFind V3
149 Reagent Kit (cat #C34880).

150

151 **2.2 Whole genome bisulfite sequencing**

152 All DNA samples were sonicated to ~350bp with a peak power of 175, duty of 10%, 200
153 cycles/burst, and a time of 47 seconds. The sonicated DNA was cleaned and
154 concentrated with Zymo gDNA clean and concentrator columns and eluted in 25 μ l EB.

155 Bisulfite conversion was performed with the Zymo EZ DNA Methylation Lightning Kit (cat
156 #11-338) using ~35 ng of each sonicated sample. Libraries were prepared using the Swift
157 ACCEL-NHS MethylSeq DNA Library Kit (cat #30096) with 7 cycles of PCR for normal-
158 input samples and 11 cycles for low-input samples. Libraries were pooled and a 0.85X
159 SPRI cleanup was performed on 250 μ l of the pool, eluted in 100 μ l. The library pool
160 (concentration of 3.63 ng/ μ l) was sequenced across 4 lanes of an Illumina NovaSeq 6000
161 S4 flow cell using 150 bp paired end reads.

162
163 FASTQ files for each sample were merged across lanes using FASTQ_Me (19) and
164 aligned to the hg38 genome using CpG_Me (20) with the default parameters (21–24). The
165 alignment pipeline includes trimming adapters and correcting for methylation bias,
166 screening for contaminating genomes, aligning to the reference genome, removing PCR
167 duplicates, calculating coverage and insert size, and extracting CpG methylation to
168 generate a cytosine report (CpG count matrix) and a quality control (**QC**) report. Global
169 methylation for each sample was calculated as the total number of methylated CpG
170 counts divided by the total number of CpG counts from CpG count matrices. From the 90
171 samples sequenced, four samples were removed from analysis: two due to high levels of
172 sequence duplication and two due to missing sample data.

173

174 **2.3 Genome-wide DNA methylation arrays**

175 In addition to WGBS, existing DNA methylation data was available from NDBS for each
176 sample from Illumina Infinium MethylationEPIC (EPIC) DNA methylation arrays (17). In
177 brief, DNA was isolated from a separate one-third portion of the NDBS, bisulfite
178 conversion performed as above, and DNA samples were block-randomized (ensuring
179 equivalent distribution of sex and race/ethnicity on each plate) for EPIC arrays (17). QC

180 of DNA methylation array data was conducted in R using “minfi”, “SeSAMe”, and “noob”
181 packages, and trisomy 21 was confirmed from copy-number variation plots generated
182 using the “conumee” package, as described (17). DMRs associated with DS-CHDs were
183 investigated using the ipDMR method with the ENmix R package (25).

184

185 **2.4 Cell type estimation**

186 To estimate nucleated cell proportions in NDBS samples, we used the EPIC array data to
187 perform reference-based deconvolution using the Identifying Optimal Libraries (IDOL)
188 algorithm (26). Briefly, “estimateCellCounts2” function from the “FlowSorted.Blood.EPIC”
189 R package was used to estimate proportions of CD8+ T lymphocytes (**CD8T**), CD4+ T
190 lymphocytes (**CD4T**), natural killer (**NK**) cells, B lymphocytes (**B cell**), monocytes,
191 granulocytes, and nucleated red blood cells (**nRBC**), using cord blood cell reference
192 samples included in the “FlowSorted.CordBloodCombined.450k” R package.

193

194 **2.5 Sample trait analysis**

195 Newborn sample traits of global CpG methylation, birthweight, gestational age of delivery,
196 age of blood collection, race, ethnicity, and cell type proportions were correlated using
197 Pearson’s method with the Hmisc package v4.7.1 and *p*-values were adjusted by FDR
198 (0.05 threshold) using the corr.test function in the Psych package v2.2.9 in Rv4.1.3. DS-
199 CHD vs DS non-CHD samples (sex-combined and sex-segregated) were tested for
200 differences across sample traits using Welch’s unpaired variances *t*-test with GraphPad
201 Prism v9.4.1. Stepwise forward logistic regression was performed to determine the
202 variables that best predicted CHD in each sex using the glm (family = binomial) function
203 in R v4.1.3. Stepwise linear regression was performed to determine the variables that
204 best predicted global CpG methylation in each sex using the lm function in R v4.1.3.

205

206 **2.6 DMR analysis from WGBS**

207 DMRs for DS-CHD vs DS non-CHD in the WGBS data were called for Sex Combined,
208 Females Only, and Males Only samples using DMRichR v1.7.3 (16) and R version 4.1.0.
209 Default parameters were used to identify DMRs containing at least 5 CpGs with at least a
210 5% methylation difference between groups, with each CpG requiring at least 1x coverage
211 in at least 75% of samples. DMRichR uses bsseq (27) to extract methylation levels from
212 cytosine reports and dmrseq (28) to identify DMRs. The dmrseq algorithm detects
213 candidate regions whose smoothed pooled methylation proportion show differences
214 between groups, then assesses the significance of candidate regions through permutation
215 testing of the pooled null distribution to calculate p-values that are then FDR corrected to
216 generate q-values (28). In all three comparisons (Sex Combined, Females Only, and
217 Males Only), we adjusted for sample traits that were correlated with global methylation ($|r|$
218 >0.2): age of blood collection and all cell types. Sex was additionally adjusted for in the
219 Sex Combined analysis. Gestational age and birthweight met this cut-off in males, but not
220 females, and were not corrected for because the effect of gestational age on DNA
221 methylation has been found to mostly be due to nRBC proportion (29) and birthweight is
222 largely dependent on gestational age. Sex chromosomes were included in Females Only
223 and Males Only comparison but not the Sex Combined comparison. The sex of each
224 sample was confirmed by the number of reads of sex chromosomes as previously
225 described (16).

226
227 Principal component analysis (**PCA**) was performed using smoothed methylation values
228 over the DMRs identified in each comparison to test for separation of CHD and non-CHD
229 samples. Data was standardized so each variable had a mean of 0 and standard deviation
230 of 1, and principal components were selected by parallel analysis from 1000 permutations
231 using GraphPad Prism v9.4.1. The two principal components that explained the greatest

232 variance in the data were selected for graphing and samples were color-coded by CHD
233 and non-CHD. Sex specificity of the DMRs was tested by obtaining smoothed methylation
234 values over DMRs from the Males Only comparison in female samples and over DMRs
235 from the Females Only comparison in male samples, and PCA was performed as
236 explained above.

237
238 Machine learning algorithms implemented through DMRichR were used to identify
239 minimal DMRs for classifying samples as CHD or non-CHD (16). Random forest
240 algorithms from the Boruta package (30) and support vector machine algorithms from the
241 sigFeature package (31) were used to build binary classification models and rank the
242 DMRs by importance for the feature selection analyses. Minimal DMRs were selected as
243 those that were identified in both lists and were in the top 1%.

244
245 DS-CHD DMRs from Sex Combined, Females Only, and Males Only comparisons were
246 overlapped by genomic coordinates using rtracklayer v1.54.0 (32) and GenomicRanges
247 v1.46.1 (33), and the venn diagram was made with VennDiagram v1.7.3 (34) in R v4.1.3.

248

249 **2.7 Enrichment testing and gene ontology from WGBS DMRs**

250 DMRs from all comparisons were tested for enrichment in chromosome location
251 compared to background regions using the Database for Annotation, Visualization and
252 Integrated Discovery (DAVID), 2021 version (35,36). DMRs were tested for enrichment in
253 genic (promoter, 5'UTR, exon, intron, 3'UTR, downstream, intergenic) and CpG (island,
254 shore, shelf, open sea) contexts compared to background regions using DMRichR (16).
255 The significance of genic and CpG annotations were tested using Fisher's exact test and
256 FDR correction. DMRs were mapped to genes on the hg38 genome using TxDb. Gene

257 ontology enrichment was performed using rGREAT (37), with genomic coordinates of
258 DMRs tested relative to background regions using the “oneClosest” rule.

259

260 **2.8 Replication of WGBS CHD DMRs in independent DS newborn study**

261 DMRs were tested for replication in a previously published DS NDBS WGBS dataset with
262 10 non-CHD (2 female, 8 male) and 11 CHD (6 female, 5 male) individuals (16).
263 Unadjusted smoothed methylation values were calculated in replication dataset samples
264 over DMR genomic coordinates from Sex Combined, Females Only, and Males Only
265 comparisons using the getMeth function of the bsseq R package (27). Unpaired t-tests
266 were calculated using the smoothed methylation values for replication CHD vs non-CHD
267 samples and p -values were corrected by FDR using GraphPad Prism v9.4.1.

268

269 **2.9 Comparison of WGBS CHD DMRs and background regions with DS vs TD NDBS** 270 **samples**

271 DS-CHD DMRs and background regions were tested for overlap with DMRs associated
272 with DS in a previous epigenome-wide association study that included 21 DS (8 female,
273 13 male) and 32 TD (16 female, 16 male) NDBS samples with WGBS data (16).
274 Unadjusted smoothed methylation values were calculated in replication dataset samples
275 over DMR and background region genomic coordinates from Sex Combined, Females
276 Only, and Males Only analyses using the getMeth function of the bsseq R package (27).
277 Unpaired t-tests were calculated for DS vs TD using the smoothed methylation values of
278 the replication dataset and p -values were corrected by the FDR method using GraphPad
279 Prism v9.4.1. Potential differences between the proportions of DS-CHD DMRs and
280 background regions that were significantly differentially methylated in DS vs TD or
281 methylated in the same direction in DS vs TD as DS-CHD vs DS non-CHD were calculated
282 using the z-test for two population proportions.

283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308

3. Results

3.1 Sample traits were not different in DS-CHD cases compared to DS non-CHD controls

We quantitated DNA methylation by EPIC array and WGBS in DNA isolated from NDBS from 86 individuals with DS, 45 of whom also had a CHD. Overall, our cohort had more females ($n = 54$, CHD = 27, non-CHD = 27) than males ($n = 32$, CHD = 18, non-CHD = 14) and a high proportion of Hispanic participants ($n = 57$ (63%)), compared to non-Hispanic white ($n = 17$ (19.8%)), non-Hispanic Asian ($n = 8$ (9.3%)), and non-Hispanic Black ($n = 4$ (4.7%)) participants; however, there were no significant differences for sex or race/ethnicity between DS-CHD and DS non-CHD newborns (**Table 1**) (**Supplemental Table S3**). In addition, birthweight, gestational age, and age at blood collection did not differ significantly between DS-CHD and DS non-CHD newborns (**Table 1**) (**Supplemental Table S3**).

The estimated cell type proportions (CD8T, CD4T, NK, B cell, monocytes, granulocytes, nRBC) in newborn blood were highly variable across samples, particularly for nRBC and granulocyte proportions (**Supplemental Table S2**). All cell types were positively correlated with one another, except nRBCs which were negatively correlated with all other cell types (**Supplemental Table S4**) (**Supplemental Figure S1**). Most cell types (CD8T, CD4T, NK, monocytes, nRBC) were also significantly (unadjusted $p < 0.05$) correlated with age of blood collection and all cell types were significantly correlated with WGBS global methylation levels, supporting the adjustment for cell types in our DMR analyses. Cell type proportions did not differ significantly between DS-CHD and DS non-CHD newborns overall, or in sex-stratified comparisons (**Table 1**) (**Supplemental Table S3**).

309
310

Table 1. Sample traits in DS-CHD cases and DS non-CHD controls

	All samples (n = 86)	DS-CHD (n = 45)	DS non-CHD (n = 41)
	Mean or n (SD or %)	Mean or n (SD or %)	Mean or n (SD or %)
Global methylation	79.3 (3.9)	79.0 (4.3)	79.5 (3.4)
CD8T	0.05 (0.03)	0.05 (0.03)	0.05 (0.04)
CD4T	0.12 (0.08)	0.13 (0.09)	0.11 (0.07)
NK	0.03 (0.02)	0.03 (0.03)	0.03 (0.02)
B cells	0.007 (0.009)	0.006 (0.009)	0.007 (0.01)
Monocytes	0.07 (0.04)	0.07 (0.05)	0.07 (0.04)
Granulocytes	0.58 (0.21)	0.54 (0.23)	0.63 (0.17)
nRBCs	0.12 (0.23)	0.15 (0.27)	0.09 (0.19)
Birthweight (grams) ¹	3018 (633)	2953 (636)	3092 (630)
Gestational age (days) ²	266 (17)	266 (16)	267 (18)
Age of blood collection (hours)	62 (57)	63 (49)	62 (65)
Sex			
Female	54 (62.8%)	27 (60%)	27 (65.9%)
Male	32 (37.2%)	18 (40%)	14 (34.1%)
Race/ethnicity			
Asian (non-Hispanic)	8 (9.3%)	6 (13.3%)	2 (4.9%)
Black (non-Hispanic)	4 (4.7%)	3 (6.7%)	1 (2.4%)
White (non-Hispanic)	17 (19.8%)	9 (20%)	8 (19.5%)
Hispanic	57 (66.3%)	27 (60%)	30 (73.2%)

311
312
313
314

¹ Missing data from 1 sample (DS non-CHD)

² Missing data from 5 samples (4 DS-CHD, 1 DS non-CHD)


315 **3.2 WGBS of newborn blood DNA detects global hypomethylation in DS-CHD males**
316 **compared to DS non-CHD males due to elevated nRBC proportions**

317 To assess the reproducibility of EPIC array and WGBS methylation quantitation, we
318 examined global CpG methylation levels from the two platforms and found that EPIC array
319 beta values (**Supplemental Table S5**) were lower than WGBS global methylation values
320 across all samples, but very strongly correlated ($r = 0.9716$, $p < 0.0001$) (**Supplemental**
321 **Figure S2**). While a few samples had notably low global CpG methylation levels (<70%
322 from WGBS), these samples were not removed from analysis because their other QC
323 metrics were acceptable and their corresponding array beta values were also low,
324 suggesting it was not a technical error.

325
326 Using WGBS data, we first assessed whether global CpG methylation levels differed
327 between DS-CHD and DS non-CHD newborns. There was no significant difference
328 overall, but when stratified by sex we found significant hypomethylation in DS-CHD males
329 compared with DS non-CHD males (unadjusted $p < 0.05$), a pattern that was not seen in
330 females (**Figure 1A-B**) (**Supplemental Figure S3**) (**Supplemental Table S3**). We
331 confirmed by logistic regression that global methylation was the most predictive variable
332 of CHD in males ($p = 0.101$), while CD4T cell proportion was the most predictive variable
333 in females ($p = 0.0681$) (**Supplemental Table S6**). Because nRBCs are known to have
334 lower methylation levels than other cell types in blood (38) and their proportion in blood
335 samples varies widely across individuals (39) in negative association with global
336 methylation (38,40), we investigated the relationship between nRBC proportion and global
337 methylation in our samples. In both females and males, nRBC proportion was significantly
338 negatively correlated with global methylation levels (**Figure 1C-D**) (**Supplemental Table**
339 **S4**) (**Supplemental Figure S1**) and was the most predictive variable of global methylation
340 in linear regression models (females $p < 2E-16$, males $p = 2.12E-9$) (**Supplemental Table**
341 **S6**). Presence of CHD predicted global methylation levels in males ($p = 0.0618$) much
342 better than in females ($p = 0.981$), but addition of nRBC proportion as an adjustment
343 covariate decreased the strength of this relationship (males, $p = 0.237$) (**Supplemental**
344 **Table S6**).

345
346 While proportion of nRBCs in the nucleated cell population is typically very low, with a
347 median of 0 for the estimated nRBC proportions across samples in our study, we identified
348 12 out of 32 male samples with nRBC proportions $> 1\%$, of which 10 (83%) had a CHD
349 (**Supplemental Table S2**) (**Supplemental Figure S3**). In contrast, we identified 24/54
350 females with nRBC proportions $> 1\%$ of which only 50% ($n=12$) had a CHD. In a sensitivity

351 analysis, we removed five male samples that had notably high nRBC levels (>20%) and
352 corresponding low global methylation levels and saw that global methylation in DS-CHD
353 vs DS non-CHD male samples were no longer significantly different ($p = 0.1865$)
354 (**Supplemental Table S3**). Females showed high interindividual variation in global
355 methylation levels and nRBC proportions in both CHD and non-CHD groups, while CHD
356 males showed much more variation (similar to females) than non-CHD males
357 (**Supplemental Figure S3**).
358



359
360 **Figure 1. Global hypomethylation in DS-CHD males vs DS non-CHD males is driven by**
361 **samples with high nRBC proportions.** Density plot of average percent smoothed
362 methylation in DS-CHD (Yes: blue) and DS non-CHD (No: red) in **A**) females (note that red
363 and blue lines are overlapping) and **B**) males. Percent global methylation correlated with

364 nRBC proportion in **C**) females (Pearson's $r = -0.93$, $p = 2.16E-24$) and **D**) males (Pearson's
365 $r = -0.84$, $p = 2.13E-9$)
366

367 **3.3 Sex-stratified DMRs distinguish DS-CHD from DS non-CHD samples better than** 368 **sex-combined DMRs**

369 Next, using WGBS data we investigated whether there were DMRs associated with DS-
370 CHDs in Sex Combined, Females Only, and Males Only comparison groups to
371 characterize both sex-specific and sex-independent patterns in DS-CHD methylation. We
372 adjusted for confounding variables that were associated with global methylation ($|r| > 0.2$):
373 age of blood collection and all cell type proportions, as well as sex (specific for the Sex
374 Combined comparison) (**Supplemental Figure S2**) (**Supplemental Table S4**).


375
376 The Sex Combined comparison yielded 58 significant by permutation ($p < 0.05$) DMRs
377 (**Supplemental Table S7**). In Females Only, we found 341 DMRs (**Supplemental Table**
378 **S8**), whereas in Males Only we found 3,938 DMRs (**Figure 2A**) (**Supplemental Table**
379 **S9**). Samples with low methylation levels across Males Only DMRs corresponded with
380 those with low global methylation. In a sensitivity analysis excluding the five male samples
381 with nRBC proportions $> 20\%$, we identified 2,474 Males Only DMRs (**Supplemental**
382 **Table S10**).

383
384 DMR hierarchal clustering and principal component analysis (**PCA**) showed that CHD and
385 non-CHD samples did not separate completely, although sex stratification improved the
386 distinction (**Figure 2A-B**). Using machine learning feature selection, we identified a
387 minimal set of 19 Males Only DMRs that could distinguish CHD from non-CHD samples
388 (**Figure 2C**) (**Supplemental Table S11**). The five male samples with high nRBCs and low
389 methylation across DMRs did not have outlier methylation values across the 19 minimal
390 DMRs, showing that the most predictive DMRs were not driven by outliers. In the Males

391 Only sensitivity analysis (with 5 samples with nRBC >20% removed), 13 minimal DMRs
392 distinguished CHD from non-CHD, with four overlapping with those from the Males Only
393 minimal selection using all samples: *DCAF1*, *LARGE2*, *LOC105379273*, *SYT9*
394 **(Supplemental Table S11)**. In the other comparisons, 6 Sex Combined and 3 Females
395 Only DMRs were identified by the feature selection but could not cleanly distinguish CHD
396 from non-CHD samples **(Supplemental Figure S4) (Supplemental Table S11)**.

397
398 In the replication dataset of WGBS from NDBS of 21 children with DS, 11 with CHD (6
399 females, 5 males) and 10 without CHD (2 females, 8 males) (16), we found 26 (46.4%) of
400 the 56 Sex Combined DMRs that were covered in the replication study were methylated
401 in the same direction in both groups **(Supplemental Table S12)**, while 161/329 (48.9%)
402 of Females Only **(Supplemental Table S13)** and 2,229/3,938 (56.7%) of Males Only
403 DMRs **(Supplemental Table S14)** were methylated in the same direction. Few DMRs
404 were significantly differentially methylated (unadjusted $p < 0.05$) in the replication dataset,
405 with 2 Sex Combined, 9 Females Only, and 68 Males Only meeting this cutoff.

406
407 In DMR analysis using EPIC array data, there were no significant DMRs associated with
408 DS-CHDs, likely due to the EPIC array only covering ~3% of CpGs covered by WGBS
409 (data not shown).



410

411

412

Figure 2. DMR profiles of CHD vs non-CHD in Sex Combined, Females Only, and Males Only comparisons within DS. A) Heatmaps of nominally significant ($p < 0.05$) DMRs


413 from DS-CHD vs DS non-CHD samples in Sex Combined, Females Only, and Males Only
414 comparisons. All heatmaps show hierarchical clustering of Z-scores, which are the number
415 of standard deviations from the mean of non-adjusted percent smoothed individual
416 methylation values for each DMR. **B)** PCA analysis using the smoothed methylation values
417 of all DMRs from the Sex Combined and Females Only comparisons and the 1000 most
418 significant DMRs in the Males Only comparison. **C)** Hierarchical clustering heatmap of the
419 machine learning feature selection analysis of the consensus DMRs from the Males Only
420 comparison.
421

422 **3.4 DS-CHD DMRs are sex-specific, with a small fraction overlapping across sexes**

423 We next examined similarities and differences in DMRs across females and males. In the
424 Sex Combined comparison, 60% of DMRs were hypomethylated in CHD compared to
425 non-CHD samples, while 40% of Females Only DMRs and 96% of Males Only DMRs were
426 hypomethylated (**Figure 3A**). In our Males Only sensitivity analysis that removed samples
427 with nRBC proportions >20%, 82% of DMRs were hypomethylated. To test the sex
428 specificity of Females Only and Males Only DMRs, we analyzed the smoothed methylation
429 values over DMRs from the Males Only comparison in female samples and from the
430 Females Only comparison in male samples and found that CHD and non-CHD samples
431 did not separate by PCA (**Supplemental Figure S5**). Females and males also did not
432 separate by hierarchal clustering or PCA in the Sex Combined comparison (**Figure 2A**)
433 (**Supplemental Figure S6**).

434
435 DMR genomic coordinates from all comparisons were then overlapped to identify sex-
436 specific vs sex-independent regions. Only 4 DMRs overlapped across all three
437 comparisons, 22 across Sex Combined and Females Only comparisons, 10 across Sex
438 Combined and Males Only comparisons, and 4 across Males Only and Females Only
439 comparisons (**Figure 3B**). All overlapping DMRs between comparison groups were
440 methylated in the same direction except for the 4 overlapping between Females Only and
441 Males Only comparisons (but not the Sex Combined comparison), which showed

442 methylation in opposite directions (**Figure 3C**). The 4 DMRs identified in all three
 443 comparisons mapped to *CDH22*, *ZNF890P*, *DIRC3*, and *TLL10-AS1* genes.




444

445 **Figure 3. Overlapping CHD DMRs across Sex Combined, Female Only, and Male Only**
 446 **comparisons within DS. A)** The percent of DMRs which were hypermethylated versus
 447 hypomethylated in each of the three comparisons. **B)** Venn diagram reflecting the numbers
 448 of unique and overlapping DMR genomic coordinates across the three comparisons. **C)** DS-
 449 CHD DMRs which overlap in two or more comparisons mapped to genes. Red indicates
 450 hypermethylation in CHD compared to non-CHD while blue represents hypomethylation,
 451 with stronger shades representing a greater percent methylation difference. Grey is used
 452 when a DMR was not called for that comparison. Black dots indicate methylation in the

453 same direction in the discovery and replication datasets (10 non-CHD (2 female, 8 male)
454 and 11 CHD (6 female, 5 male)) while white dots indicate methylation in the opposite
455 direction in the two datasets. No dot means that the DMR genomic coordinates were not
456 covered in the replication dataset.
457

458 **3.5 DS-CHD DMRs are enriched for gene exons, CpG islands, and bivalent chromatin**

459 CHD DMRs from Sex Combined, Females Only, and Males Only comparisons were
460 analyzed for enrichment compared to background regions by distribution across
461 chromosomes, genic and CpG contexts, histone marks, and chromatin states. In all three
462 comparisons, DMRs were distributed throughout the genome (**Supplemental Figure S7**),
463 though Males Only DMRs showed significant enrichment (FDR <0.05) on chromosomes
464 2, 4, 5, 8, 18, and 21, while Females Only DMRs showed nominal enrichment (unadjusted
465 $p < 0.05$) on chromosomes 20, X, and 21 (**Supplemental Table S15**). There was
466 significant positive enrichment in all comparisons for gene exons and CpG islands (**Figure**
467 **4**) (**Supplemental Figures S8, S9**) (**Supplemental Table S16**), as well as the
468 transcriptionally repressive H3K27me3 histone mark and bivalent enhancers and
469 transcription start sites based on chromatin states (**Supplemental Figures S10-S15**). Sex
470 differences were also observed, with significant positive enrichment for CpG shelves in
471 the Females Only comparison and significant negative enrichment in the Males Only
472 comparison. The Females Only DMRs also showed enrichment for H3K4me3, associated
473 with active/poised chromatin, while the Males Only DMRs showed enrichment for
474 H3K9me3, another repressive mark (**Supplemental Figure S13**). Hypomethylated
475 regions showed overall stronger enrichment for histone marks and chromatin states
476 compared to hypermethylated regions (**Supplemental Figures S14-S15**).




477

478 **Figure 4. Annotation enrichments of CHD DMRs. A)** Genic and **B)** CpG enrichments of
 479 all significant ($p < 0.05$) DMRs from Sex Combined, Females Only, and Males Only
 480 comparisons. DMRs were compared to background regions for each comparison and
 481 significance was determined by the Fisher's test and FDR correction. * = $q < 0.05$.
 482

483 3.6 DS-CHD DMRs map to genes that are enriched for cardiac terms

484 DMRs mapped to genes were analyzed for enrichment across Gene Ontology terms (p
 485 < 0.05) related to biological processes, cellular components, and molecular functions. All
 486 comparisons showed enrichment for heart-related terms, such as cardiac muscle

487 contraction (Sex Combined) (**Figure 5**), dorsal/ventral pattern formation, which includes
488 formation of the embryonic heart tube (Females Only), and development of the septum
489 primum, which divides the heart atrium into left and right and whose developmental failure
490 can lead to AVSD (Males Only) (**Supplemental Figure S16**) (**Supplemental Tables S17-**
491 **S19**). Genes contributing to the heart-related terms included *FGF12*, *PIK3CA*, *TNNI3*,
492 *PDE4D*, *ACVR1*, *GATA4*, and others (**Table 2**). Enriched terms also included immune-
493 related biological processes, such as platelet activation and innate immune response (Sex
494 Combined) (**Figure 5**).



495
496 **Figure 5. Gene ontology enrichments.** Bar plot of the fifteen most significant GO
497 enrichments for biological processes in DS-CHD versus DS non-CHD DMRs from the Sex
498 Combined comparison.
499

500 **Table 2. Heart-related biological processes identified from DMR Gene Ontology**

Comparison	GO Term	Genes
Sex Combined	cardiac muscle contraction	<i>FGF12,PIK3CA,TNNI3</i>
	striated muscle contraction	<i>FGF12,PIK3CA,TNNI3</i>
	heart contraction	<i>FGF12,PIK3CA,TNNI3</i>
	heart process	<i>FGF12,PIK3CA,TNNI3</i>
	ductus arteriosus closure	<i>TFAP2B</i>
	determination of dorsal/ventral asymmetry	<i>NBL1</i>
	cellular response to erythropoietin	<i>CD40</i>
	regulation of cardiac conduction	<i>NPR2,TNNI3</i>
	muscle contraction	<i>FGF12,PIK3CA,TNNI3</i>
	skeletal muscle contraction	<i>TNNI3</i>
Females Only	dorsal/ventral pattern formation	<i>FOXP1,GLI2,GREM2,INTU,MDFI,SMAD6,SUFU,TCTN1</i>
	negative regulation of relaxation of cardiac muscle	<i>PDE4D</i>
	negative regulation of heart contraction	<i>AGTR2,PDE4D</i>
	adrenergic receptor signaling pathway involved in heart process	<i>PDE4D</i>
	regulation of heart rate by chemical signal	<i>PDE4D</i>
	regulation of relaxation of cardiac muscle	<i>PDE4D</i>
	aorta development	<i>SMAD6,SUFU,TFAP2B,TGFB2</i>
	regulation of ventricular cardiac muscle cell membrane repolarization	<i>ANK2,WDR1</i>
Males Only	septum primum development	<i>ACVR1,GATA4,GJA5,SOX4,TGFB2</i>
	atrial septum primum morphogenesis	<i>ACVR1,GATA4,SOX4,TGFB2</i>
	atrioventricular canal development	<i>CHD7,FOXP4,HAS2,PTPN11</i>
	adult heart development	<i>ADRA1A,CHD7,HAND2,SCUBE1,TCAP</i>
	artery smooth muscle contraction	<i>AGT,EDN1,EDN2,HTR2A,MKKS</i>
	right ventricular compact myocardium morphogenesis	<i>CHD7</i>
	atrial septum secundum morphogenesis	<i>GATA4</i>
	positive regulation of heart rate	<i>ADRA1A,ADRB1,EDN1,EDN2,EDN3,KCNQ1,PDE4D,RYR2,SCN3B,TACR3,UTS2</i>

cardiac muscle hypertrophy	<i>AGT, GATA4, GATA6, HDAC4, KDM4A, LEP, PP3CA, RYR2, TCAP, TIAM1, TTN</i>
positive regulation of heart contraction	<i>ADRA1A, ADRB1, EDN1, EDN2, EDN3, KCNQ1, PDE4D, RGS2, RYR2, SCN3B, TACR3, TGFB2, UTS2</i>
septum secundum development	<i>GATA4</i>
cardiac septum morphogenesis	<i>ACVR1, BMP4, BMP7, CHD7, FZD1, FZD2, GATA4, GATA6, GJA5, HES1, HEY1, HEYL, ISL1, JAG1, MSX2, NRP1, PARVA, PITX2, PROX1, RARB, SMAD6, SMAD7, SOX11, SOX4, TBX3, TGF B2, TGFBR2, ZFPM2</i>

501

502 3.7 DS-CHD DMRs are also differentially methylated in DS vs typical development

503 NDBS

504 DS-CHD DMRs were tested for comparison in previously published DS vs TD NDBS
505 WGBS samples (16) to evaluate the hypothesis that if DS-CHD is a more severe form of
506 DS, CHD DMRs should be partially shared with DS vs TD DMRs (**Table 3**). Of the 58 Sex
507 Combined CHD DMRs, 16 (27.6%) were significantly differentially methylated ($p < 0.05$) in
508 DS vs TD samples (**Supplemental Table S20**), 9 of which (56.3%) were methylated in
509 the same direction in DS vs TD samples as DS-CHD vs DS non-CHD samples. Of
510 Females Only DMRs, 42/341 (12.3%) were significantly differentially methylated ($p < 0.05$)
511 in DS vs TD, with 28 (66.7%) methylated in the same direction (**Supplemental Table S21**)
512 and of Males Only DMRs, 602/3,938 (15.3%) were significantly differentially methylated
513 ($p < 0.05$) in DS vs TD, with 528 (87.7%) methylated in the same direction (**Supplemental**
514 **Table S22**). These numbers decreased in a sensitivity analysis with the Males Only DMRs
515 generated with five samples with nRBC > 0.2 removed, where 334/2,454 (13.6%) covered
516 DMRs were significantly ($p < 0.05$) differentially methylated in DS vs TD male samples, of
517 which 248/334 (74.3%) were methylated in the same direction. For all three comparisons,
518 there was a trend towards more CHD DMRs being significantly differentially methylated in
519 DS vs TD samples compared to background regions (z-test for two population proportions,
520 Sex Combined $p = 0.08364$, Females Only $p = 0.0536$, Males Only $p = 0.0601$) (**Figure 6A**).

521 In Males Only, significantly more DMRs were methylated in the same direction in DS vs
 522 TD as DS-CHD vs DS non-CHD compared to background regions (z-test for two
 523 population proportions, $p < 0.00001$), though this was not true for Sex Combined or
 524 Females Only CHD DMRs (**Figure 6B**). Of DMRs that were significantly differentially
 525 methylated ($q < 0.05$) in DS vs TD samples, 5/9 (55.6%) Sex Combined, 6/8 (75%)
 526 Females Only, and 15/16 (93.85%) Males Only DMRs were hypomethylated in DS
 527 compared to TD samples. With the exception of an exon in *ZNF735*, which was
 528 significantly hypermethylated ($q < 0.05$) in both the Sex Combined and Females Only DS
 529 vs TD comparisons, all DMRs were specific to one comparison (**Figure 6C**).


530

531 **Table 3. Significance and direction of CHD DMRs and background regions in DS vs**
 532 **TD samples**
 533

	DMRs	Background Regions
Sex Combined	<i>n</i> (%)	<i>n</i> (%)
Total	58	5,363
Omitted	0	28
$p < 0.05$	16 (27.6)	995 (18.7)
$p \geq 0.05$	42 (72.4)	4,340 (81.3)
Same direction	34 (58.6)	3,274 (61.4)
Opposite direction	24 (41.4)	2,061 (38.6)
Females Only	<i>n</i> (%)	<i>n</i> (%)
Total	341	11,998
Omitted	2	147
$p < 0.05$	42 (12.4)	1,101 (9.3)
$p \geq 0.05$	297 (87.6)	10,750 (90.7)
Same direction	172 (50.7)	6,304 (53.2)
Opposite direction	167 (49.3)	5,547 (46.8)
Males Only	<i>n</i> (%)	<i>n</i> (%)
Total	3,938	127,819
Omitted	26	1,413
$p < 0.05$	602 (15.4)	18,099 (14.3)
$p \geq 0.05$	3,310 (84.6)	108,307 (85.7)
Same direction	3,001 (76.7)	90,954 (72.0)
Opposite direction	911 (23.3)	35,452 (28.0)

534

535 Same direction indicates methylation is in same direction (hypo or hyper) in DS vs TD as in
 536 DS-CHD vs non-CHD



537

538 **Figure 6. Comparison of DS-CHD DMRs with DS vs TD samples. A)** Percent of DS-CHD
539 DMRs and background regions that were significantly differentially methylated in DS vs TD
540 samples. Z-test for two population proportions, Sex Combined ($z = 1.7343$, two-tailed $p =$
541 0.08364) Females Only ($z = 1.93$, two-tailed $p = 0.0536$), Males Only ($z = 1.8808$, two-tailed p
542 $= 0.0601$). $+ = p < 0.1$. **B)** Percent of DS-CHD DMRs that were methylated in same direction
543 in DS vs TD as in DS-CHD vs DS non-CHD. Z-test for two populations proportions, Sex
544 Combined ($z = -0.4274$, two-tailed $p = 0.6672$), Females Only ($z = -0.8936$, two-tailed p
545 $= 0.37346$), Males Only ($z = 6.5357$, two-tailed $p < 0.00001$). $**** = p < 0.00001$. **C)** Heatmap
546 showing DS-CHD DMRs that were significant ($q < 0.05$) in DS vs TD samples mapped to
547 genes. Red indicates hypermethylation in CHD compared to non-CHD while blue represents
548 hypomethylation, with stronger shades representing a greater percent methylation difference
549 and gray meaning that that DMR was not significant for that comparison. Black dots indicate
550 that methylation is in the same direction for DS vs TD as DS-CHD vs DS non-CHD while
551 white dots indicate methylation is in the opposite direction.
552

553 4. Discussion

554 This is the largest study to date to investigate epigenetic variation associated with CHDs in
555 individuals with DS. Although non-syndromic CHDs have been widely studied, there has been

556 relatively little research into the etiology and biomarkers of CHDs in individuals with DS,
557 despite nearly half of the DS population presenting this phenotype (2–5). To address this gap,
558 we assessed DS-CHD methylation in DNA isolated from NDBSs, an understudied and
559 accessible biospecimen that enables the analysis of epigenomic changes during the *in utero*
560 and perinatal periods that are associated with phenotypic traits of interest. We confirmed the
561 reproducibility of DNA extraction and bisulfite conversion from NDBSs by finding a high
562 correlation ($r = 0.9716$) between global methylation levels from WGBS and EPIC array, which
563 used different punches from the same blood spots.

564
565 Although newborn blood typically shows ~79-84% global CpG methylation from WGBS
566 (16,40), we found a range of 60.8-82.9% in our NDBS DNA. The samples with notably low
567 WGBS global methylation also had low EPIC array beta values and passed other QC metrics,
568 indicating that technical errors do not explain the result, although we cannot exclude non-
569 biological causes. Previous studies have found a trend towards global hypomethylation in DS
570 compared to TD NDBS (16), which may explain our findings. We further found that global
571 methylation was lower in DS-CHD males compared to DS non-CHD males, though this
572 relationship was not found in females. Global methylation was strongly negatively correlated
573 with, and predicted by, nRBC proportion in both sexes. Although nRBCs typically constitute a
574 very small proportion of nucleated cells, we found nRBC proportions ranged widely in both
575 sexes and were evenly spread amongst CHD and non-CHD females but in males, 10/12
576 samples with nRBC >1% were CHD positive. This discrepancy in the relationship between
577 high nRBCs and CHD in males versus females likely explains the association between CHD
578 and global hypomethylation in males and the lack of such association among females, given
579 the strong effects of nRBC proportions on global methylation levels in DS newborns (17). The
580 etiology of the male-specific association between high nRBCs and CHD in newborns with DS
581 remains to be determined.

582

583 Previous studies have reported high nRBC levels in DS newborns with pulmonary
584 hypertension (41), as well as in hypoxic-related pregnancy situations, such as preeclampsia,
585 maternal obesity and diabetes, maternal smoking, and prenatal exposure to infection (42–48).
586 Increased nRBC counts are thought to follow fetal hypoxemia through elevated erythropoietin
587 (**EPO**), a hormone that stimulates production of erythrocytes (red blood cells) in an effort to
588 increase oxygen delivery to tissues (49,50). Interestingly, EPO is higher in children with DS-
589 CHD compared to non-syndromic CHD (51). Because CHDs reduce cerebral oxygen (52)
590 and may induce fetal hypoxemia (53), high nRBC proportions may be more common in
591 individuals with CHDs and, in particular, in DS newborns with CHDs given the placental
592 abnormalities seen in fetuses with trisomy 21 (PMID: 31683073). However, we could not
593 confirm this hypothesis with our sample size. Moreover, nRBC proportions were estimated
594 from DNA methylation array data, rather than using actual cell counts, and cell type
595 deconvolution in individuals with DS may be confounded by the presence of blast cells that
596 are common in DS and not accounted for in the analysis (17). Cell composition deconvoluted
597 from DNA methylation arrays has been previously reported to be altered in DS blood
598 compared to non-DS blood (54). Further, we previously reported a positive relationship
599 between high nRBC proportions in newborns with DS and presence of somatic *GATA1*
600 mutations, indicative of transient abnormal myelopoiesis (**TAM**) or silent TAM, and it is
601 possible that the relationship between CHD and global hypomethylation in males may be
602 confounded by this preleukemic condition (17). Understanding of the complex relationships
603 between CHDs in DS, global methylation, cell type proportions, sex, and fetal hypoxia would
604 benefit from further investigation.

605

606 In our WGBS regional analysis, we found over 10-fold the number of CHD-associated DMRs
607 in DS males than in females, and even fewer DMRs in the Sex Combined analysis. Reflecting

608 our finding of global hypomethylation in CHD males, 96% of Males Only DMRs were
609 hypomethylated, a pattern not seen in the Females Only or Sex Combined analyses. All DMRs
610 were corrected for confounding factors including cell type proportions, suggesting that nRBC
611 levels were not fully responsible for the notable proportion of hypomethylated DMRs in males,
612 although we cannot rule out residual confounding due to nRBCs or unmeasured traits related
613 to nRBCs. Additionally, removing the five male samples with nRBC proportions > 20%
614 resulted in 82% hypomethylated DMRs, suggesting that these five samples alone were not
615 driving the signature of hypomethylation in DS-CHD males. Some DMRs from all comparisons
616 were also differentially methylated in DS vs TD samples, and in males, a significantly higher
617 proportion of DMRs were methylated in the same direction in DS vs TD and DS-CHD vs DS
618 non-CHD compared to background regions. These results suggest that male DS patients with
619 CHD may represent a more severe epigenomic signature than is observed for DS versus TD,
620 although this may also reflect the higher nRBC proportions that have been reported in
621 newborns with DS than in TD newborns (Muskens 2021). In contrast, female DS cases with
622 CHD are somewhat epigenetically distinct from female and male DS cases without CHD.
623 Response to hypoxia may play a role in these differences. DS newborns, even those without
624 CHDs, experience more hypoxemia events than newborns with TD (55), and CHDs further
625 induce fetal hypoxemia (53). A wide variety of sex differences have been observed in
626 response to hypoxia in both humans and animal models (56,57), including differences in gene
627 expression profiles of female vs male mice in cardiac adaptive responses to hypoxia (58).
628 These sex-specific responses to hypoxia may be reflected in the methylome, which is known
629 to be influenced by gestational hypoxia (59) (reviewed in (60)). Identification of genes and
630 pathways whose methylation and/or gene expression is altered in DS, CHDs, and hypoxia
631 may help elucidate the sex specificity of molecular mechanisms related to DS-CHD.
632

633 Although we did not find any significant DMRs associated with DS-CHD after FDR-correction,
634 the nominally significant DMRs were enriched for genes implicated in cardiac processes,
635 suggesting that at least some of the DMRs may reflect true epigenetic mechanisms associated
636 with DS-CHD development. In particular, Males Only DMRs selected by machine learning
637 feature selection were able to distinguish CHD from non-CHD samples and frequently
638 mapped to genes associated with CHDs or cardiomyopathies, including *FUNDC1* (61), *ETV5*
639 (62,63), *SYT9* (64), *CAMTA1* (65), *GRIA4* (66), and *IGF1R* (67–70). Additionally, DMRs that
640 contributed to enrichment for heart-related gene ontology terms included *TNNI3*, a cardiac-
641 specific gene that codes for cardiac troponin I, whose absence leads to severe pediatric
642 cardiomyopathy (71), and *GATA4*, which encodes a member of the GATA family of zinc finger
643 transcription factors, is essential for mammalian cardiac development, and whose sequence
644 variants have been identified in individuals with CHDs (72). Whether the differential
645 methylation in the genes we identified plays an etiologic role or reflects epigenomic effects
646 downstream of the development of CHDs remains to be determined.

647
648 While this is, to our knowledge, the largest DNA methylation study of CHDs in DS, our sample
649 size of 86 DS newborns may still have limited our ability to detect genome-wide significant (q
650 <0.05) DMRs. Additionally, only around half of DMRs in all comparisons were methylated in
651 the same direction in the discovery and replication groups, potentially due to the very small
652 sample sizes and absence of confounding variable data to use for correction in the replication
653 group, as well as high interindividual variation in methylation. The genes to which our DMRs
654 mapped did not heavily coincide with those identified in previous epigenetic studies of DS-
655 CHD (73,74), likely because those studies included small numbers of DS subjects, used non-
656 NDBS biospecimens assayed with array-based methods, which do not have good coverage
657 over the regions we detected using WGBS, and did not account for cell type heterogeneity.
658 One exception to this is that we identified a DMR in the Males Only comparison that mapped

659 to *SHC3*, a gene that was differentially expressed in DS individuals with an endocardial
660 cushion CHD (73). The DS field would benefit from further studies into the etiology and
661 biomarkers of phenotypes common in the DS population, including CHDs.

662

663 **5. Conclusions**

664 Overall, this study presents the largest investigation of epigenetic variation associated with
665 CHDs in individuals with DS. We identified sex-specific global and regional methylation
666 differences in DS-CHD vs DS non-CHD newborns. Specifically, in males we found that
667 newborns with DS-CHD were globally hypomethylated compared to DS newborns without
668 CHD, a finding that appeared to be driven by differences in nRBC proportions between the
669 two groups. At the regional level, the majority of CHD DMRs identified by sex stratification did
670 not overlap by genomic coordinates, suggesting sex differences in the molecular signature of
671 CHDs in DS. Gene ontology analysis of DMRs from both sexes revealed enrichment in
672 pathways related to the heart, and some DS-CHD DMRs were also differentially methylated
673 in DS vs TD samples. Our results provide insight into the development of CHDs in newborns
674 with DS, pointing to sex-specific differences that warrant further investigation, and suggest
675 that DNA methylation may serve as a useful biomarker for investigating the variability of
676 clinical features within the genetic disorder of DS.

677

678

679

680 **DECLARATIONS**

681 **Ethics approval and consent to participate**

682 This study was approved by Institutional Review Boards at the California Health and Human
683 Services Agency, University of Southern California, and University of California Davis.

684

685 **Consent for publication**

686 Deidentified NDBS were obtained from the California Biobank Program (SIS request number
687 572), with a waiver of consent from the Committee for the Protection of Human Subjects of
688 the State of California.

689

690 **Availability of data and materials**

691 This study used biospecimens from the California Biobank Program. Any uploading of
692 genomic data (including genome-wide DNA methylation data) and/or sharing of these
693 biospecimens or individual data derived from these biospecimens has been determined to
694 violate the statutory scheme of the California Health and Safety Code Sections 124980(j),
695 124991(b), (g), (h), and 103850 (a) and (d), which protect the confidential nature of
696 biospecimens and individual data derived from biospecimens. Should we be contacted
697 regarding individual-level data contributing to the findings reported in this study, inquiries will
698 be directed to the California Department of Public Health Institutional Review Board to
699 establish an approved protocol to utilize the data, which cannot otherwise be shared peer-
700 to-peer.

701

702 Code is available at

703 https://github.com/juliamouat/DownSyndrome_CongenitalHeartDefect_DNAMethylation

704

705 **Competing interests**

706 The authors declare that they have no competing interests.

707

708 **Funding**

709 This work was supported by National Institutes of Health NIEHS T32 ES007059 (JSM) and
710 P30 ES023513 (JML); an Alex's Lemonade Stand Foundation 'A' Award (AJD); Canadian

711 Institutes of Health Research (CIHR) postdoctoral fellowship MFE-146824 (BIL); CIHR

712 Banting postdoctoral fellowship BPF-162684 (BIL)

713

714 **Authors' contributions**

715 BIL, AJD, and JML designed the study. AJD and JML supervised the project. AJD, PJL,

716 JPW, and JMS prepared data. SSM performed DNA extractions. SL performed array

717 analysis. JSM performed bioinformatic analyses. JSM, AJD, and JML interpreted results.

718 JSM drafted the manuscript and made figures and tables. PJL, AJD, and JML revised the

719 manuscript. All authors reviewed and approved the final manuscript.

720

721 **Acknowledgements**

722 A subset of biospecimens and/or data used in this study were obtained from the California

723 Biobank Program at the California Department of Public Health (CDPH), SIS request

724 number 572, in accordance with Section 6555(b), 17 CCR. The CDPH is not responsible for

725 the results or conclusions drawn by the authors of this publication.

726

727 We thank Robin Cooley and Steve Graham (Genetic Disease Screening Program, CDPH)

728 for their assistance and expertise in the procurement and management of NDBS

729 specimens. We thank the DNA Technologies and Expression Analysis Core at the UC Davis

730 Genome Center for library preparation and WGBS.

731

732

733 **REFERENCES**

734

735 1. Antonarakis SE, Skotko BG, Rafii MS, Strydom A, Pape SE, Bianchi DW, et al. Down
736 syndrome. Nat Rev Dis Primers. 2020 Feb 6;6(1):9.

737 2. Dobosz A, Bik-Multanowski M. Long-term Trends in the Prevalence of Congenital Heart
738 Defects in Patients with Down Syndrome in Southern Poland. Dev Period Med. 2019 Oct
739 27;23(3):184–9.

- 740 3. Irving CA, Chaudhari MP. Cardiovascular abnormalities in Down's syndrome: spectrum,
741 management and survival over 22 years. *Arch Dis Child*. 2012 Apr;97(4):326–30.
- 742 4. Laursen HB. Congenital heart disease in Down's syndrome. *Br Heart J*. 1976 Jan;38(1):32–
743 8.
- 744 5. Weijerman ME, van Furth AM, Vonk Noordegraaf A, van Wouwe JP, Broers CJM, Gemke
745 RJJ. Prevalence, neonatal characteristics, and first-year mortality of Down syndrome: a
746 national study. *J Pediatr*. 2008 Jan;152(1):15–9.
- 747 6. Mai CT, Isenburg JL, Canfield MA, Meyer RE, Correa A, Alverson CJ, et al. National
748 population-based estimates for major birth defects, 2010–2014. *Birth Defects Res*. 2019 Nov
749 1;111(18):1420–35.
- 750 7. Korbel JO, Tirosh-Wagner T, Urban AE, Chen XN, Kasowski M, Dai L, et al. The genetic
751 architecture of Down syndrome phenotypes revealed by high-resolution analysis of human
752 segmental trisomies. *Proc Natl Acad Sci U S A*. 2009 Jul 21;106(29):12031–6.
- 753 8. Ackerman C, Locke AE, Feingold E, Reshey B, Espana K, Thusberg J, et al. An Excess of
754 Deleterious Variants in VEGF-A Pathway Genes in Down-Syndrome-Associated
755 Atrioventricular Septal Defects. *Am J Hum Genet*. 2012 Oct 5;91(4):646–59.
- 756 9. Ramachandran D, Mulle JG, Locke AE, Bean LJH, Rosser TC, Bose P, et al. Contribution of
757 Copy Number Variation to Down Syndrome-associated Atrioventricular Septal Defects.
758 *Genet Med*. 2015 Jul;17(7):554–60.
- 759 10. Ramachandran D, Zeng Z, Locke AE, Mulle JG, Bean LJH, Rosser TC, et al. Genome-Wide
760 Association Study of Down Syndrome-Associated Atrioventricular Septal Defects. *G3*
761 (Bethesda). 2015 Jul 20;5(10):1961–71.
- 762 11. Rambo-Martin BL, Mulle JG, Cutler DJ, Bean LJH, Rosser TC, Dooley KJ, et al. Analysis
763 of Copy Number Variants on Chromosome 21 in Down Syndrome-Associated Congenital
764 Heart Defects. *G3 (Bethesda)*. 2017 Nov 15;8(1):105–11.
- 765 12. Sailani MR, Makrythanasis P, Valsesia A, Santoni FA, Deutsch S, Popadin K, et al. The
766 complex SNP and CNV genetic architecture of the increased risk of congenital heart defects
767 in Down syndrome. *Genome Res*. 2013 Sep;23(9):1410–21.
- 768 13. Trevino CE, Holleman AM, Corbitt H, Maslen CL, Rosser TC, Cutler DJ, et al. Identifying
769 genetic factors that contribute to the increased risk of congenital heart defects in infants with
770 Down syndrome. *Sci Rep*. 2020 Oct 22;10(1):18051.
- 771 14. Cao J, Wu Q, Huang Y, Wang L, Su Z, Ye H. The role of DNA methylation in syndromic
772 and non-syndromic congenital heart disease. *Clinical Epigenetics*. 2021 Apr 26;13(1):93.
- 773 15. Vecoli C, Pulignani S, Foffa I, Andreassi MG. Congenital Heart Disease: The Crossroads of
774 Genetics, Epigenetics and Environment. *Curr Genomics*. 2014 Oct;15(5):390–9.

- 775 16. Laufer BI, Hwang H, Jianu JM, Mordaunt CE, Korf IF, Hertz-Picciotto I, et al. Low-Pass
776 Whole Genome Bisulfite Sequencing of Neonatal Dried Blood Spots Identifies a Role for
777 RUNX1 in Down Syndrome DNA Methylation Profiles. *Hum Mol Genet.* 2020 Oct 1;
- 778 17. Muskens IS, Li S, Jackson T, Elliot N, Hansen HM, Myint SS, et al. The genome-wide
779 impact of trisomy 21 on DNA methylation and its implications for hematopoiesis. *Nat*
780 *Commun.* 2021 Feb 5;12:821.
- 781 18. Croen LA, Shaw GM, Jensvold NG, Harris JA. Birth defects monitoring in California: a
782 resource for epidemiological research. *Paediatric and Perinatal Epidemiology.*
783 1991;5(4):423–7.
- 784 19. Laufer BI. FASTQ_Me [Internet]. 2020 [cited 2023 Feb 28]. Available from:
785 https://github.com/ben-laufer/FASTQ_Me
- 786 20. Laufer BI. CpG_Me [Internet]. 2022 [cited 2022 Jan 20]. Available from:
787 https://github.com/ben-laufer/CpG_Me
- 788 21. Ewels P, Magnusson M, Lundin S, Källér M. MultiQC: summarize analysis results for
789 multiple tools and samples in a single report. *Bioinformatics.* 2016 Oct 1;32(19):3047–8.
- 790 22. Krueger F, Andrews SR. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq
791 applications. *Bioinformatics.* 2011 Jun 1;27(11):1571–2.
- 792 23. Laufer BI, Neier K, Valenzuela AE, Yasui DH, Schmidt RJ, Lein PJ, et al. Placenta and fetal
793 brain share a neurodevelopmental disorder DNA methylation profile in a mouse model of
794 prenatal PCB exposure. *Cell Reports.* 2022 Mar;38(9):110442.
- 795 24. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads.
796 *EMBnet.journal.* 2011 May 2;17(1):10–2.
- 797 25. Xu Z, Xie C, Taylor JA, Niu L. ipDMR: identification of differentially methylated regions
798 with interval P-values. *Bioinformatics.* 2020 Aug 17;37(5):711–3.
- 799 26. Koestler DC, Jones MJ, Usset J, Christensen BC, Butler RA, Kobor MS, et al. Improving
800 cell mixture deconvolution by identifying optimal DNA methylation libraries (IDOL). *BMC*
801 *Bioinformatics.* 2016 Mar 8;17:120.
- 802 27. Hansen KD, Langmead B, Irizarry RA. BSmooth: from whole genome bisulfite sequencing
803 reads to differentially methylated regions. *Genome Biology.* 2012 Oct 3;13(10):R83.
- 804 28. Korthauer K, Chakraborty S, Benjamini Y, Irizarry RA. Detection and accurate false
805 discovery rate control of differentially methylated regions from whole genome bisulfite
806 sequencing. *Biostatistics.* 2019 Jul 1;20(3):367–83.
- 807 29. Haftorn KL, Denault WRP, Lee Y, Page CM, Romanowska J, Lyle R, et al. Nucleated red
808 blood cells explain most of the association between DNA methylation and gestational age.
809 *Commun Biol.* 2023 Feb 27;6(1):1–11.

- 810 30. Kursa MB, Rudnicki WR. Feature Selection with the Boruta Package. *Journal of Statistical*
811 *Software*. 2010 Sep 16;36:1–13.
- 812 31. Das P, Roychowdhury A, Das S, Roychoudhury S, Tripathy S. sigFeature: Novel Significant
813 Feature Selection Method for Classification of Gene Expression Data Using Support Vector
814 Machine and t Statistic. *Frontiers in Genetics* [Internet]. 2020 [cited 2023 Feb 13];11.
815 Available from: <https://www.frontiersin.org/articles/10.3389/fgene.2020.00247>
- 816 32. Lawrence M, Gentleman R, Carey V. rtracklayer: an R package for interfacing with genome
817 browsers. *Bioinformatics*. 2009 Jul 15;25(14):1841–2.
- 818 33. Lawrence M, Huber W, Pagès H, Aboyoun P, Carlson M, Gentleman R, et al. Software for
819 Computing and Annotating Genomic Ranges. *PLOS Computational Biology*. 2013 Aug
820 8;9(8):e1003118.
- 821 34. Chen H, Boutros PC. VennDiagram: a package for the generation of highly-customizable
822 Venn and Euler diagrams in R. *BMC Bioinformatics*. 2011 Jan 26;12(1):35.
- 823 35. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene
824 lists using DAVID bioinformatics resources. *Nat Protoc*. 2009;4(1):44–57.
- 825 36. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the
826 comprehensive functional analysis of large gene lists. *Nucleic Acids Res*. 2009 Jan;37(1):1–
827 13.
- 828 37. McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, Lowe CB, et al. GREAT improves
829 functional interpretation of cis-regulatory regions. *Nat Biotechnol*. 2010 May;28(5):495–
830 501.
- 831 38. de Goede OM, Lavoie PM, Robinson WP. Characterizing the hypomethylated DNA
832 methylation profile of nucleated red blood cells from cord blood. *Epigenomics*. 2016
833 Nov;8(11):1481–94.
- 834 39. Salas LA, Zhang Z, Koestler DC, Butler RA, Hansen HM, Molinaro AM, et al. Enhanced
835 cell deconvolution of peripheral blood using DNA methylation for high-resolution immune
836 profiling. *Nat Commun*. 2022 Feb 9;13(1):761.
- 837 40. Mordaunt CE, Jianu JM, Laufer B, Zhu Y, Dunaway KW, Bakulski KM, et al. Cord blood
838 DNA methylome in newborns later diagnosed with autism spectrum disorder reflects early
839 dysregulation of neurodevelopmental and X-linked genes [Internet]. *Genomics*; 2019 Nov
840 [cited 2020 Apr 15]. Available from: <http://biorxiv.org/lookup/doi/10.1101/850529>
- 841 41. Nitzan I, Kasirer Y, Mimouni FB, Fink D, Wasserteil N, Hammerman C, et al. Elevated
842 Nucleated Red Blood Cells in Neonates with Down Syndrome and Pulmonary Hypertension.
843 *J Pediatr*. 2019 Oct;213:232–4.

- 844 42. Aali BS, Malekpour R, Sedig F, Safa A. Comparison of maternal and cord blood nucleated
845 red blood cell count between pre-eclamptic and healthy women. *J Obstet Gynaecol Res.*
846 2007 Jun;33(3):274–8.
- 847 43. Baschat AA, Gungor S, Kush ML, Berg C, Gembruch U, Harman CR. Nucleated red blood
848 cell counts in the first week of life: a critical appraisal of relationships with perinatal
849 outcome in preterm growth-restricted neonates. *Am J Obstet Gynecol.* 2007
850 Sep;197(3):286.e1-8.
- 851 44. de Goede OM, Razzaghian HR, Price EM, Jones MJ, Kobor MS, Robinson WP, et al.
852 Nucleated red blood cells impact DNA methylation and expression analyses of cord blood
853 hematopoietic cells. *Clinical Epigenetics.* 2015 Sep 11;7(1):95.
- 854 45. Hermansen M. Nucleated red blood cells in the fetus and newborn. *Arch Dis Child Fetal*
855 *Neonatal Ed.* 2001 May;84(3):F211–5.
- 856 46. Redline RW. Elevated circulating fetal nucleated red blood cells and placental pathology in
857 term infants who develop cerebral palsy. *Hum Pathol.* 2008 Sep;39(9):1378–84.
- 858 47. Yeruchimovich M, Dollberg S, Green DW, Mimouni FB. Nucleated red blood cells in
859 infants of smoking mothers. *Obstet Gynecol.* 1999 Mar;93(3):403–6.
- 860 48. Yeruchimovich M, Mimouni FB, Green DW, Dollberg S. Nucleated red blood cells in
861 healthy infants of women with gestational diabetes. *Obstet Gynecol.* 2000 Jan;95(1):84–6.
- 862 49. Bedrick AD. Nucleated red blood cells and fetal hypoxia: a biologic marker whose ‘timing’
863 has come? *J Perinatol.* 2014 Feb;34(2):85–6.
- 864 50. Teramo KA, Widness JA. Increased Fetal Plasma and Amniotic Fluid Erythropoietin
865 Concentrations: Markers of Intrauterine Hypoxia. *Neonatology.* 2009 Feb;95(2):105–16.
- 866 51. Zakharchenko L, EL-Khuffash A, Hurley T, Kelly L, Melo A, Padden M, et al. Infants with
867 Down syndrome and congenital heart disease have altered peri-operative immune responses.
868 *Pediatr Res.* 2022 Mar 29;1–8.
- 869 52. Morton PD, Korotcova L, Lewis BK, Bhuvanendran S, Ramachandra SD, Zurakowski D, et
870 al. Abnormal neurogenesis and cortical growth in congenital heart disease. *Sci Transl Med.*
871 2017 Jan 25;9(374):eaah7029.
- 872 53. Peyvandi S, Xu D, Wang Y, Hogan W, Moon-Grady A, Barkovich AJ, et al. Fetal Cerebral
873 Oxygenation Is Impaired in Congenital Heart Disease and Shows Variable Response to
874 Maternal Hyperoxia. *Journal of the American Heart Association.* 2021 Jan 5;10(1):e018777.
- 875 54. Zhang Z, Stolrow HG, Christensen BC, Salas LA. Down Syndrome Altered Cell
876 Composition in Blood, Brain, and Buccal Swab Samples Profiled by DNA-Methylation-
877 Based Cell-Type Deconvolution. *Cells.* 2023 Jan;12(8):1168.

- 878 55. Krahn KN, Nagraj VP, McCulloch MA, Zimmet AM, Fairchild KD. Hypoxemia in infants
879 with Trisomy 21 in the Neonatal Intensive Care Unit. *J Perinatol*. 2021 Jun;41(6):1448–53.
- 880 56. Horiuchi M, Kirihara Y, Fukuoka Y, Pontzer H. Sex differences in respiratory and
881 circulatory cost during hypoxic walking: potential impact on oxygen saturation. *Sci Rep*.
882 2019 Jul 2;9(1):9550.
- 883 57. Mayoral SR, Omar G, Penn AA. Sex Differences in a Hypoxia Model of Preterm Brain
884 Damage. *Pediatr Res*. 2009 Sep;66(3):248–53.
- 885 58. Bohuslavová R, Kolář F, Kuthanová L, Neckář J, Tichopád A, Pavlinkova G. Gene
886 expression profiling of sex differences in HIF1-dependent adaptive cardiac responses to
887 chronic hypoxia. *Journal of Applied Physiology*. 2010 Oct;109(4):1195–202.
- 888 59. Zhu Y, Gomez JA, Laufer BI, Mordaunt CE, Mouat JS, Soto DC, et al. Placental methylome
889 reveals a 22q13.33 brain regulatory gene locus associated with autism. *Genome Biology*.
890 2022 Feb 16;23(1):46.
- 891 60. Ma Q, Xiong F, Zhang L. Gestational hypoxia and epigenetic programming of brain
892 development disorders. *Drug Discov Today*. 2014 Dec;19(12):1883–96.
- 893 61. Liu L, Li Y, Chen Q. The Emerging Role of FUNDC1-Mediated Mitophagy in
894 Cardiovascular Diseases. *Frontiers in Physiology* [Internet]. 2021 [cited 2023 Mar 2];12.
895 Available from: <https://www.frontiersin.org/articles/10.3389/fphys.2021.807654>
- 896 62. Liu Y, Lu P, Wang Y, Morrow BE, Zhou B, Zheng D. Spatiotemporal Gene Coexpression
897 and Regulation in Mouse Cardiomyocytes of Early Cardiac Morphogenesis. *J Am Heart*
898 *Assoc*. 2019 Jul 19;8(15):e012941.
- 899 63. Tan WLW, Anene-Nzeliu CG, Wong E, Lee CJM, Tan HS, Tang SJ, et al. Epigenomes of
900 Human Hearts Reveal New Genetic Variants Relevant for Cardiac Disease and Phenotype.
901 *Circulation Research*. 2020 Aug 28;127(6):761–77.
- 902 64. Xie HH, Li J, Li PQ, Zhang AA, Li Y, Wang YZ, et al. A genetic variant in a homocysteine
903 metabolic gene that increases the risk of congenital cardiac septal defects in Han Chinese
904 populations. *IUBMB Life*. 2017 Sep;69(9):700–5.
- 905 65. Song K, Backs J, McAnally J, Qi X, Gerard RD, Richardson JA, et al. The Transcriptional
906 Coactivator CAMTA2 Stimulates Cardiac Growth by Opposing Class II Histone
907 Deacetylases. *Cell*. 2006 May 5;125(3):453–66.
- 908 66. Izarzugaza JMG, Ellesøe SG, Doganli C, Ehlers NS, Dalgaard MD, Audain E, et al. Systems
909 genetics analysis identifies calcium-signaling defects as novel cause of congenital heart
910 disease. *Genome Medicine*. 2020 Aug 28;12(1):76.
- 911 67. Benbouchta Y, De Leeuw N, Amasdl S, Sbiti A, Smeets D, Sadki K, et al. 15q26 deletion in
912 a patient with congenital heart defect, growth restriction and intellectual disability: case
913 report and literature review. *Italian Journal of Pediatrics*. 2021 Sep 16;47(1):188.

- 914 68. González-Guerra JL, Castilla-Cortazar I, Aguirre GA, Muñoz Ú, Martín-Estal I, Ávila-
915 Gallego E, et al. Partial IGF-1 deficiency is sufficient to reduce heart contractibility,
916 angiotensin II sensibility, and alter gene expression of structural and functional cardiac
917 proteins. PLOS ONE. 2017 Aug 14;12(8):e0181760.
- 918 69. Huynh K, McMullen JR, Julius TL, Tan JW, Love JE, Cemerlang N, et al. Cardiac-specific
919 IGF-1 receptor transgenic expression protects against cardiac fibrosis and diastolic
920 dysfunction in a mouse model of diabetic cardiomyopathy. Diabetes. 2010 Jun;59(6):1512–
921 20.
- 922 70. Ock S, Lee WS, Ahn J, Kim HM, Kang H, Kim HS, et al. Deletion of IGF-1 Receptors in
923 Cardiomyocytes Attenuates Cardiac Aging in Male Mice. Endocrinology. 2016
924 Jan;157(1):336–45.
- 925 71. Kühnisch J, Herbst C, Al-Wakeel-Marquard N, Dartsch J, Holtgrewe M, Baban A, et al.
926 Targeted panel sequencing in pediatric primary cardiomyopathy supports a critical role of
927 TNNI3. Clinical Genetics. 2019;96(6):549–59.
- 928 72. Tomita-Mitchell A, Maslen CL, Morris CD, Garg V, Goldmuntz E. GATA4 sequence
929 variants in patients with congenital heart disease. J Med Genet. 2007 Dec;44(12):779–83.
- 930 73. Dobosz A, Grabowska A, Bik-Multanowski M. Hypermethylation of NRG1 gene correlates
931 with the presence of heart defects in Down’s syndrome. J Genet. 2019 Dec;98:110.
- 932 74. Serra-Juhé C, Cuscó I, Homs A, Flores R, Torán N, Pérez-Jurado LA. DNA methylation
933 abnormalities in congenital heart disease. Epigenetics. 2015 Jan 14;10(2):167–77.
- 934